Corporate History

Dendright Pty Limited was established in 2005 to commercialise the discovery that the body's immune response to self-antigen could be “re-educated” to silence rather than to activate. The technology targets the dendritic cells which are key cells in the immune system that present antigens to T cells. The therapeutic response may be both long-lasting and fine-tuned to the pathology at play. 

The discovery was made by  Professor Ranjeny Thomas, Dr Brendan O’Sullivan and Dr Nigel Davies at the University of Queensland Diamantina Institute.

This discovery was patented by UniQuest Pty Limited, the main commercialisation company of The University of Queensland. Dendright has an exclusive worldwide license from UniQuest to commercialise this invention. 

Dendright is wholly owned by UniQuest Pty Limited.

Dendright’s first commercial agreement was announced in January 2012. It is a strategic research collaboration with Janssen-Cilag Pty Ltd, one of the Janssen pharmaceutical companies.

Dendright has been highly successful in attracting non-dilutive finance via competitive commercial grant funding. This includes the Queensland Government’s Innovation Start-up Scheme and the Australian Government’s Biotechnology Innovation Fund.